Skip to main content Accessibility help
×
Home
  • Print publication year: 2018
  • Online publication date: May 2018

Chapter 7 - Which Drug is Best?

Related content

Powered by UNSILO
Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., Arellano, F. M. (2010) Suicide-related events in patients treated with antiepileptic drugs. New Engl J Med 2010;363: 542–51.
Baulac, M., Leon, T., O'Brien, T. J., Whalen, E., Barrett, J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 2010;91: 10–9.
Beyenburg, S., Stavem, K., Schmidt, D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010 Jan; 51(1): 726.
Bill, P. A., Vigonius, U., Pohlmann, H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997 Jun; 27(3): 195204.
Brodie, M. J., Overstall, P. W., Giorgi, L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999 Oct; 37(1): 81–7.
Brodie, M. J., Perucca, E., Ryvlin, P., et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68: 402–8.
Brodie, M. J., Richens, A., Yuen, A. W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995 Feb 25; 345(8948): 476–9.
Callaghan, B. C., Anand, K., Hesdorffer, D., Hauser, W. A., French, J. A. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007;62: 382–9.
Chiron, C., Dumas, C., Jambaqué, I., Mumford, J., Dulac, O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997 Jan; 26(2): 389–95.
Chiron, C., Marchand, M. C., Tran, A., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356: 1638–42.
Darke, K., Edwards, S. W., Hancock, E., et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010;95: 382–6.
Elger, C. E., Schmidt, D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008;12: 501–39.
Engel, J. Jr., Pedley, T. (Editors). Epilepsy: a comprehensive textbook. Second edition. Vols. 1–3. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, PA, 2007.
FDA Alert [12/12/2007]. Information on Carbamazepine. 2007. www.fda.gov/cder/drug/infopage/carbamazepine/default.htm
FDA Safety Alert [2011]. Topamax (topiramate): Label change-risk for development of cleft lip and /or cleft palate in newborns. www.fda.gove/SafetyInformation/SafteyAlertsforHumanMedicalProducts/ucm24577.htm posted 3.4.2011
French, J. A., Kanner, A. M., Bautista, J., et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004a; 62: 1252–60.
French, J. A., Kanner, A. M., Bautista, J., et al. Efficacy and tolerability of the new antiepileptic drugs. II. Treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment. Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004b; 62(8): 1261–73.
Glauser, T., Ben-Menachem, E., Bourgeois, B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006 Jul; 47(7): 1094–120.
Glauser, T. A., Cnaan, A., Shinnar, S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362: 790–9.
Glauser, T., Kluger, G., Sachdeo, R., et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70: 1950–8.
Guerreiro, M. M., Vigonius, U., Pohlmann, H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997 Jun; 27(3): 205–13.
Löscher, W., Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52(4): 657–78.
Luciano, A. L., Shorvon, S. D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62(4): 375–81.
Marson, A. G., Appleton, R., Baker, G. A., et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007 Oct; 11(37): iiiiv, ixx, 1134.
Mattson, R. H., Cramer, J. A., Collins, J. F., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985 Jul 18; 313(3): 145–51.
Mattson, R. H., Cramer, J. A., Collins, J. F., et al. Comparison of valproate with carbamazepine for focal epilepsy in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic–clonic seizures in adults. N Engl J Med 1992.
Mintzer, S., Mattson, R. T. Should non enzyme-inducing AEDs be preferred over enzyme-inducing AEDs as first-line agents? Epilepsia 2009 Sep; 50(Suppl 8): 4250.
Mula, M., Sander, J. W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30: 555–67.
Privitera, M. D., Brodie, M. J., Mattson, R. H., et al., Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 Mar; 107(3): 165–75.
Saetre, E., Perucca, E., Isojärvi, Y., et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007;48: 1292–302.
Scheffer, I. E., Zhang, Y. H., Jansen, F. E., et al. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev 2009 May; 31(5): 394400.
Schmidt, D. Single drug therapy for intractable epilepsy. J Neurol 1983;229: 221–6.
Schmidt, D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav 2009;15: 5665.
Schmidt, D. Efficacy of new antiepileptic drugs. Epilepsy Curr 2011;11(1): 911.
Schmidt, D., Beyenburg, S. Antiepileptic drugs. In Side effects of drugs. Annual 31, Aronson, J. K. (ed.), pp. 105–48. Elsevier: Amsterdam, 2009.
Tomson, T., Battino, D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009;27: 993–1002.
US Food and Drug Administration. FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications, 2008. www.fda.gov/
Wilby, J., Kainth, A., Hawkins, N., et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9(15): 1157, iiiiv.